Skip to main content
. 2000 Apr 4;97(8):4192–4197. doi: 10.1073/pnas.050417697

Figure 1.

Figure 1

Vaccine trial design. Sixteen monkeys were divided into four experimental groups and were immunized with: 1) 10 mg of sham plasmid; 2) 5 mg of HIV-1 Env 89.6P and 5 mg of SIV mac239 Gag DNA vaccines; 3) DNA vaccines and IL-2/Ig protein; or 4) DNA vaccines and IL-2/Ig plasmid. Five milligrams of sham plasmid was administered to the animals that received the DNA vaccines alone on day 2 after the week 0 and week 4 immunizations. IL-2/Ig protein (0.5 mg/day) was administered by twice-daily i.m. injections on days 1–14 after the week 0 and week 4 immunizations. Five milligrams of IL-2/Ig plasmid was administered on day 2 after the week 0 and week 4 immunizations. The week 8 immunization was performed without cytokine administration.